Nautilus introduced the Voyager Platform in St. Louis, showcasing its benchtop design that combines integrated reagents, fluidics, ultra-dense nano-array flow cells and machine-learning algorithms. The system enables Iterative Mapping of up to 10 billion intact protein molecules and proteoforms in a single run with high accuracy, precision and reproducibility, targeting next-generation proteomics across diverse research fields.

In January 2026 Nautilus launched its Iterative Mapping Early Access Program, initially offering fee-for-service projects through Nautilus Proteomics Analysis Services. The program’s first offering is the Tau Proteoforms assay, quantifying up to 768 full-length tau proteoform groups that existing methods cannot distinguish, supporting biomarker and therapeutic research in neurodegenerative diseases.

Nautilus plans a broader commercial launch of the Voyager Platform in late 2026, with a limited number of instrument placements available to select researchers in advance. Accepted projects receive guidance from Nautilus scientists on data interpretation, quantification and analysis, paving the way for full market introduction by year-end.

A field evaluation unit installed at the Buck Institute for Research on Aging produced novel, highly reproducible insights into tau proteoform biology, validating platform readiness for broader applications. Joint research findings highlighted the ability to reveal previously inaccessible proteoforms, underscoring the platform’s potential to advance biomarker discovery and therapeutic innovation.